Andreou Chrysafis, Pal Suchetan, Rotter Lara, Yang Jiang, Kircher Moritz F
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Mol Imaging Biol. 2017 Jun;19(3):363-372. doi: 10.1007/s11307-017-1056-z.
The fields of biomedical nanotechnology and theranostics have enjoyed exponential growth in recent years. The "Molecular Imaging in Nanotechnology and Theranostics" (MINT) Interest Group of the World Molecular Imaging Society (WMIS) was created in order to provide a more organized and focused forum on these topics within the WMIS and at the World Molecular Imaging Conference (WMIC). The interest group was founded in 2015 and was officially inaugurated during the 2016 WMIC. The overarching goal of MINT is to bring together the many scientists who work on molecular imaging approaches using nanotechnology and those that work on theranostic agents. MINT therefore represents scientists, labs, and institutes that are very diverse in their scientific backgrounds and areas of expertise, reflecting the wide array of materials and approaches that drive these fields. In this short review, we attempt to provide a condensed overview over some of the key areas covered by MINT. Given the breadth of the fields and the given space constraints, we have limited the coverage to the realm of nanoconstructs, although theranostics is certainly not limited to this domain. We will also focus only on the most recent developments of the last 3-5 years, in order to provide the reader with an intuition of what is "in the pipeline" and has potential for clinical translation in the near future.
近年来,生物医学纳米技术和治疗诊断学领域呈指数级增长。世界分子影像学会(WMIS)的“纳米技术与治疗诊断学中的分子影像”(MINT)兴趣小组应运而生,旨在为WMIS内部以及世界分子影像大会(WMIC)提供一个更具组织性和针对性的关于这些主题的论坛。该兴趣小组于2015年成立,并在2016年WMIC期间正式启动。MINT的总体目标是将众多致力于使用纳米技术的分子影像方法的科学家与从事治疗诊断剂研究的科学家汇聚在一起。因此,MINT代表了在科学背景和专业领域方面非常多样化的科学家、实验室和研究机构,反映了推动这些领域发展的广泛材料和方法。在这篇简短的综述中,我们试图对MINT涵盖的一些关键领域提供一个简要概述。鉴于这些领域的广度以及给定的篇幅限制,我们将报道范围限制在纳米构建体领域,尽管治疗诊断学肯定不限于这一领域。我们还将仅关注过去3至5年的最新进展,以便让读者了解“正在筹备中”且在不久的将来有临床转化潜力的内容。